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Abstract
Glaucoma, the leading cause of irreversible blindness, appears in various forms. Mutations
in CYP1B1 result in primary congenital glaucoma (PCG) by an autosomal recessive mode
of inheritance while it acts as a modifier locus for primary open angle glaucoma (POAG).
We investigated the molecular basis of the variable phenotypes resulting from the defects in
CYP1B1 by using subclones of 23 CYP1B1mutants reported in glaucoma patients, in a cell
based system by measuring the dual activity of the enzyme to metabolize both retinol and
17β-estradiol. Most variants linked to POAG showed low steroid metabolism while null or
very high retinol metabolism was observed in variants identified in PCG. We examined
the translational turnover rates of mutant proteins after the addition of cycloheximide and
observed that the levels of enzyme activity mostly corroborated the translational turnover
rate. We performed extensive normal mode analysis and molecular-dynamics-simulations-
based structural analyses and observed significant variation of fluctuation in certain seg-
mental parts of the mutant proteins, especially at the B-C and F-G loops, which were
previously shown to affect the dynamic behavior and ligand entry/exit properties of the cyto-
chrome P450 family of proteins. Our molecular study corroborates the structural analysis,
and suggests that the pathologic state of the carrier of CYP1B1mutations is determined by
the allelic state of the gene. To our knowledge, this is the first attempt to dissect biological
activities of CYP1B1 for correlation with congenital and adult onset glaucomas.
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Introduction
Glaucoma represents a group of heterogeneous and complex disorders characterized by a pro-
gressive loss of retinal ganglion cells. It is the most common cause of irreversible blindness.
According to the latest estimates 5.7 million people are visually impaired and about 3.1 million
are blind due to glaucoma worldwide [1]. Among different types of glaucoma, primary congen-
ital glaucoma (PCG) is the most common childhood glaucoma that is observed in the neonatal
or infantile periods. This disorder is most likely due to developmental defects in the trabecular
meshwork and the anterior chamber angle of the eye. The mode of inheritance of PCG is pri-
marily autosomal recessive with variable penetrance [2]. On the other hand, primary open
angle glaucoma (POAG), the most common form of all types of glaucoma, is a complex disease
caused by multiple genetic and environmental factors, as well as their interactions. In this dis-
order, intra-ocular pressure (IOP) usually increases in persons older than 50 years without any
subjective symptoms until irreversible damage occurs. However, such an increase in IOP is not
a necessary condition for the disease. If the condition is left untreated, it leads to impaired
vision and, ultimately, to blindness in approximately 2% of the elderly population [3]. Trans-
mission of the disease occurs mostly in a monogenic form in juvenile onset POAG (JOAG) and
in a complex form in adults [4–6].
In 1997, cytochrome P4501B1 (CYP1B1; OMIM 601771) was first identified as a causal
gene for PCG [7]. Till date mutations in CYP1B1 are considered the primary cause of PCG in
different populations, worldwide [8–10]. For POAG, on the contrary, 16 chromosomal loci
have been mapped so far by linkage analysis (GLC1A-P) [11, 12] and at least 20 POAG suscep-
tibility genes have been identified through candidate gene analysis [12, 13]. CYP1B1mutations
have also been reported to be present in POAG, mostly in the heterozygous state [4, 6, 14, 15].
Initially, CYP1B1 was suggested to be a modifier gene for the expression of the Myocilin gene
(MYOC) in patients with JOAG [6]. However, subsequent studies have proposed that CYP1B1
may play a causative role in JOAG with a possible monogenic association in French, Indian,
and Spanish patients [4, 5, 14, 15].
CYP1B1 is a monooxygenase, which catalyzes many reactions involved in the metabolism
of endogenous compounds that include 17β-estradiol, retinals, arachidonic acid, and melato-
nin. The functional implication of CYP1B1mutations in differential disease pathogenesis,
especially in the causation of PCG and POAG is not well studied. However, it is known that ret-
inoic acid (RA) is critical for ocular development, and the role of CYP1B1 in metabolizing RA
might have an implication in the causation of PCG [16, 17]. A recent report from our group
has also shown that dysfunction in the 17β estradiol metabolizing activity of some mutants of
CYP1B1 can cause MYOC upregulation, which may lead to POAG pathogenesis [18].
In the current cell-based study, therefore, we examine the dual activity of CYP1B1 (retinol
and 17β-estradiol metabolism) using natural mutations occurring in glaucoma patients, and
we attempt to correlate the differential activity of the enzyme with the clinical phenotypes of
the patients (PCG vs POAG) carrying those mutations. We have also performed exhaustive
molecular docking, normal mode analysis (NMA) and molecular dynamics (MD) simulation
analyses to understand the structural and functional modifications in various naturally occur-
ring CYP1B1 mutations that lead to clinical phenotypes. The active site of CYP1B1 protein, as
well as its other family members, is located deep within the protein, close to the heme cofactor
[19]. Earlier studies [19–21] have demonstrated that substrate channels or tunnels influence
the kinetics of P450 family enzymes and conformational dynamics plays a crucial role in deter-
mining the entry and exit of ligands to and from the active site. Crystallography and MD simu-
lation studies on other P450 structures demonstrated the importance of the B-C loop and F-G
helix in determining active site access to the substrate [20]. In this study, we have investigated
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the tunnel properties of the PCG and POAGmutants, and their possible effects on substrate
binding. An earlier MD-based study [21] demonstrated the potential effects of only PCG caus-
ing mutations on a CYP1B1 homology model. However, in this article, we attempt to dissect
the biological activities of the protein through experimentation and dynamics-based structural
studies in order to draw correlations with both the congenital (PCG) and adult onset glaucoma
(POAG) pathogeneses.
Materials and Methods
Selection of CYP1B1 variants reported in PCG and POAG patients
In this study 23 CYP1B1missense variants were selected on the basis of (i) higher frequency of
occurrence, and (ii) a large change in the chemical nature (e.g. charge, polarity, molecular size
of the side chain etc.) of the mutated amino acid. The selected mutants reported in PCG were
mostly in homozygous or compound heterozygous condition whereas in POAG those were
mostly in heterozygous condition.
CYP1B1 variant clone preparation
A CYP1B1 true ORF clone was procured from OriGene Technologies, Rochville, USA with a
myc epitope tagged at the C-terminal. The 23 mutated clones were created by the QuikChange
II Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) using primers specific to the
gene. The mutated plasmids were verified by Sanger sequencing. Additional details of primers
are available in S1 Table.
Mammalian cell culture & transfection
HEK293T, and Human Trabecular Meshwork (TM) cell lines were maintained in DMEM
(Dulbecco’s modified Eagle Medium, GIBCO BRLWaltham, MA, USA) at pH 7.4 but the
media used for the TM cell line contained low glucose concentration (1 g/L). The identity of
the TM cell line was confirmed by upregulation of endogenous myocilin by dexamethasone
treatment as described previously [18]. The HEK293T cell line from ATCC was selected for
mammalian cell-culture experiments because they express almost no endogenous CYP1B1 as
determined by Western blot analysis (S1 Fig). The cells were grown in appropriate volume of
10% FBS in high glucose DMEM (GIBCO BRL, Waltham, MA, USA), supplemented with non-
essential amino acids (Life Technologies, Carlsbad, CA, USA), L-GlutaMAX, 1% penicillin/
streptomycin, and sodium pyruvate. All cultures were grown in a 37°C incubator with 5% CO2
under normal humidity.
6 X105 and 3X105 cells were plated on a 6 well plate and 12 well plate respectively in 10%
FBS in DMEM. Transient transfections were done with various plasmids (variant clones of
CYP1B1 generated through SDM) and Retinoic Acid Receptor Element (RARE) constructs,
procured from SA-Biosciences (QIAGEN, Hilden, Germany), using Lipofectamine 2000
reagent (Invitrogen, Waltham, MA, USA) according to the manufacturer’s protocol. Cells were
grown in DMEM serum free medium (Life Technologies, Carlsbad, CA, USA) for 6h, and then
shifted to complete growth medium.
Determination of estradiol metabolism activity of wild type (WT) and
variant CYP1B1
Estradiol metabolism activity of the WT and mutants were measured with the CYP450-GLO™
Assay kit (Promega, Madison, WI) using the protocol described previously [18] and the esti-
mation of the enzyme activities were done as mentioned below:
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First, background luminescence (no cell control) was subtracted from all test samples (WT
and all other variants) including the empty vector transfected group.
Second, the values observed for empty vector transfected cells were subtracted from values
observed for WT and other mutants. In this way the endogenous activity of CYP1B1 was taken
care of.
The enzyme activities of the mutant proteins were expressed as a percentage of the activity
retained as compared to the WT protein. Each assay was performed in triplicate and repeated
three times, and statistical significance was calculated using Student’s t-test.
Determination of retinol metabolism activity of wild type and variant
CYP1B1
To assess the retinol metabolizing activity of the CYP1B1 variants we designed an indirect
strategy. We took advantage of the ability of CYP1B1 to convert retinol into RA. We performed
sequential transient transfection of CYP1B1 constructs in HEK293T cell line followed by co-
tranfection of an inducible RARE-responsive firefly luciferase construct and another construct
constitutively expressing Renilla luciferase (SA-Biosciences, Qiagen, Germany). Cells express-
ing WT and mutant CYP1B1 proteins could then convert retinol into RA, which would eventu-
ally bind to inducible-RARE. The method is described in details.
Cells were transiently transfected with WT and variant clones of CYP1B1. After 12h RARE
constructs (SA-Biosciences, QIAGEN, Hilden, Germany) were transfected in the cell line using
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol; 16h post
transfection, retinol solution (2μM final concentration), procured from Sigma (St. Louis, MO),
was added after media change to each well (according to manufacturer protocol). The cells
were incubated for 6h.
Post retinol treated cells were washed with phosphate buffer saline (PBS) and subsequently
lysed with luciferase cell culture lysis buffer supplied with the Dual Luciferase Reporter Assay
kit (Promega, Madison, WI). After a short vortex, whole cell lysates were centrifuged at 4°C at
13,000 rpm (HERMLE Z 233 MK-2) for 1min and 10μl of the supernatants was mixed with
25μl of luciferase assay reagent-I, Firefly (FL) luminescence was measured as relative luciferase
units (RLU) in a GLOMAX luminometer (Promega, Madison, WI). Next, 25μl of Stop & Glo
solution was added to stop the reaction and Renilla Luciferase (RL) luminescence was mea-
sured. For quantifying retinol metabolism activity, the calculation method provided by the
manufacturer Cignal RARE Reporter Assay Kit (LUC), QIAGEN, Germany was followed.
First, the FL-RLU value of the negative control (a mixture of the noninducible firefly lucifer-
ase construct and the constitutively expressing Renilla luciferase construct provided in the kit)
was subtracted from the value of all test samples (WT and all other variants) including the
empty vector transfected group. Second, the luminescence value of the empty vector trans-
fected group was subtracted fromWT and other variants. Third, the FL-RLU value for each
variant was divided by the corresponding RL-RLU value to normalize for transfection effi-
ciency. The enzyme activity of the mutant proteins was expressed as percentage of the activity
retained as compared to the WT protein. Each assay was performed in triplicate and repeated
three times, and statistical significance was calculated using a Student’s t-test.
Determination of CYP1B1 variant protein turnover rate after addition of
cycloheximide (CHX)
Post transfection (14h), 10 μg/ml (final concentration) CHX solution was added in each well.
Treated cells were incubated for 12h; protein lysates were prepared at 4h intervals and analyzed
through Western blotting techniques. We optimized the concentration of CHX using WT
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variant before we used it in assay. For this purpose, we assayed the effect of 5, 10, and 15 μg/ml
concentrations of CHX onWT expression level at 4, 8 and 12h (S2 Table). We selected a 10 μg/
ml dose for our further studies as we intended to show changes in protein level in mutants
compared to WT after the addition of CHX.
Western blotting from mammalian cells
Cells were lysed using NP-40 lysis buffer (150mM Tris-Cl, 50mM EDTA, pH 8.0, 1% NP40)
supplemented with protease inhibitor cocktail (1μl/106 cell; Sigma, St. Louis, MO) and was son-
icated in a water bath for 5min. Total protein was estimated using Bradford assay (BioRad,
Herucles, CA, USA).
Approximately 20μg of total protein was separated on 10% SDS-polyacrylamide (MiniPRO-
TEAN III; BioRad, Herucles, CA, USA) and transferred onto a PVDF membrane (Hybond-P;
GE Healthcare, Bedford, UK) by electro blotting using the ECL semi-dry transfer unit (Amer-
sham Biociences, Piscataway, NJ, USA). Membranes were then blocked in 5% BSA in TBS for
2h at room temperature and incubated with the respective primary antibody anti-Myc poly-
clonal antibody for checking CYP1B1 overexpression (1:1000) (Cell Signaling Technology,
Danvers, MA,USA), anti-β-actin (1:2000) antibody (Sigma-Aldrich, St. Louis, MO, USA)]
overnight at 4°C. β-actin was used as the loading control. The membranes were washed thrice
with TBST 25mM Tris-HCl (pH 7.5), 150mMNaCl, 0.05% tween-20] at 10min interval fol-
lowed by incubation with the appropriate secondary antibody conjugated with HRP Anti-rab-
bit (1:60,000) and anti-mouse (1:2000)] (Bangalore Genei, India) for 2h at room temperature.
The secondary antibody was washed thrice with TBST followed by two washes with TBS. The
ECL-western blotting detection kit (Pierce, Waltham, MA, USA) was used for detection of
chemiluminescence. Densitometry for protein band quantitation was performed on scanned
films using Image J software on triplicated independent experiments. OD values for each
mutants was normalized to OD values of the respective β-actin band. The results were com-
pared using a Student’s t-test.
In silico CYP1B1 mutant model generation and molecular docking
analysis
The crystal structure of the human CYP1B1 protein (PDB ID: 3PM0) [22] was used for struc-
tural analysis. The mutant models of CYP1B1 were generated using the USFC Chimera v1.5.3
structure editing package [23]. Docking of retinol and 17β-estradiol to WT and mutant
CYP1B1 structures was performed using the GOLD v5.0.1 [24] package (please see S1 Method
for details about the docking protocol).
Normal mode, molecular dynamics simulation and tunnel analysis
Normal mode analysis. The NMA package of the Bio3D [25] program was used to ana-
lyze the dynamic behavior of wild type and mutant CYP1B1 structures. The average fluctua-
tions of the 7th, 8th and 9th modes were used to compare the systems.
Molecular dynamics simulation protocol. CYP1B1 monomer coordinates were collected
from the crystal structure of human cytochrome P4501B1 (PDB ID: 3PM0; chain A) [22] as
starting structure for initiating the molecular dynamics (MD) simulations. All simulations
were performed using GROMACS v4.5.3 [26]. The united atom force field GROMOS96 53a6
[27] was used to describe protein, water and ions. The GROMACS utility, pdb2gmx, was used
to rebuild hydrogen positions in the starting structure after ignoring the initial hydrogens in
the crystal structure. Both N- and C- termini of the protein were assigned neutral charges and
the side-chain functional groups of all the ionizable amino acids were allowed to acquire
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default ionization states as detected and defined by the pdb2gmx module. The protein structure
was placed at the center of the cubic box and solvated with the SPC water model [28]. Periodic
boundary condition was applied to minimize edge effects in the solvated structure. The simula-
tion protocol involved energy minimization of the system using steepest descent followed by
conjugate gradient algorithms. Next equilibration dynamics of the whole system was carried
out for 1ns; ensuring the least disturbance to the starting structure. A leap-frog algorithm was
used to integrate Newton’s equations of motion with an integration time-step of 2fs. Twin-
range cut-offs of 9Å and 14Å were applied to calculate the van der Waals interactions and the
neighbor list was updated every five steps. To compensate for truncation effects, long-range
dispersion correction was applied for energy and pressure. The electrostatics were calculated
using the Particle Mesh Ewald [29] method. System neutrality was achieved by adding six Na
+ ions as counter ions by replacing random water molecules. The LINCS [30] and SETTLE
[31] algorithms were invoked to constrain hydrogen bonds and water molecules, respectively.
The production run was performed with an NPT ensemble (at physiological temperature,
T = 303°K and pressure, P = 1 bar). The system, comprising of the whole protein and the sol-
vent, was separately coupled to the temperature bath to ensure minimum fluctuations in the
simulation temperature. During the production run Nosé-Hoover [32, 33] thermostat with
temperature coupling, TT = 0.5ps, and Parrinello-Rahman [34] barostat with pressure cou-
pling, TP = 1.0ps, were used. Each CYP1B1 WT and mutant protein was undergone for a
production simulation run of 100ns using five nodes (each having six Intel Zeon X5675 proces-
sors) on average of a high performance computer (HPC) clusters.
MD trajectory, tunnel and essential dynamics analysis. The emergent trajectories were
analyzed by employing the inbuilt tools of GROMACS v4.5.3 [26]. Chimera v1.5.3 [23] was
used for visualization and image creation. Tunnel analysis was done using CAVER 3.0 program
[35] and in-house Perl programs.
MD simulations is used to study the structural motions of proteins while essential dynamics
based approach [36] allows to obtain a concise interpretation of the protein motions from the
large amount of simulation data. Essential dynamics based approach uses principal component
analysis (PCA) to removes the linear correlations among the atomic coordinates of a protein
structure and can be described by principal components or PCs to represent a system's
motions. These individual PCs represent a set of collective motions exhibited by the 3D struc-
ture. Principal components are sorted decreasingly in representing the collective motions, e.g.
principal component 1 or PC1 will represent the largest set of collective motions of the system
followed by PC2 and PC3. In this study we have used structural ensemble of wild type and
mutant CYP1B1 structures obtained from the MD simulation to infer the essential dynamics of
the system (please see S1 Method for details about the ED analysis).
Results
Selection of mutations
More than 180 different CYP1B1 mutations are linked to different eye diseases including PCG
and POAG [9, 10], spread across the entire protein, without any clustering of mutations for a
specific disorder (S2A Fig).
For this study, 23 missense mutations were selected belonging to 3 different categories
depending on their reported roles in glaucoma pathogenesis; (a) 8 variants were reported
exclusively for PCG; (b) 6 exclusively for POAG; and (c) 9 reported for both PCG and POAG
(Table 1 and S2B Fig). The mutant proteins resulting from these variants were examined for
their biological activity with respect to retinoic acid and 17β-estradiol metabolism.
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Table 1. Genotype to Phenotype analysis for CYP1B1 variants implicated in POAG and PCG.
MutationStudied
[ref.]1
Disease (Genotype
reported)2
2nd mutation
reported (if any)3
Enzyme Activity for mutant
allele studied(% WT)4
Inferred Enzyme
Activity for
Reported Genotype
(% WT)5
Genotype to
Phenotype
correlation
(Yes/No)6
PCG POAG JOAG Retinol Steroid Retinol Steroid
p. P52L[42],[43] 0.00 ± 0.00 70.97 ± 4.36 PCG: No;
Hetero Hetero 50 85 JOAG: No
p.W57C[44, 45],[4] Homo - 221.71±16.19 337.84 ± 20.38 221 338 PCG: Yes;
Hetero 161 219 JOAG: Yes
p. G61E[44, 46],
[15, 43], [47–51]
Homo Homo 0.00 ± 0.00 0.00 ± 0.00 0 0 PCG: Yes;
Hetero Hetero R355fsX69 in PCG 50 50 POAG: Yes;
Comp.
Het.
Comp.
Het
p.Y81N* in POAG 0 for
both
5for
Y81N; 0
for fs
JOAG:Yes for
Homo, if
escaped PCG
due to
incomplete
penetrance
p. R117W[52] - - 0.00 ± 0.00 0.00 ± 0.00 PCG: No
Comp.
Het.
R469W* 62 3
p. R117P[53, 54] - - 0.00 ± 0.00 70.63 ± 2.60 PCG:
Inconclusive
(Biochem assay
not done for
R390H)
Comp.
Het.
R390H N/A N/A
p. M132R[55–57] Homo - - 0.00 ± 0.00 35.35 ± 2.03 0 36 PCG: Yes
p. E229K[10, 42,
45, 53, 54, 58–65],
[15, 43],[4, 14]
137.28 ± 6.51 167.65 ± 34.37 PCG: Nofor
Comp Het with
del mutation;
Inconclusive with
P193L (Biochem
assay not done);
Hetero Hetero Hetero 119 134 POAG:
Inconclusive;
JOAG: No
Comp.
Het.
P193L, c.1064-
1076del
69 for
del
84 for
del
p. F261L[42, 66] - - 243.15±15.48 22.22 ± 1.86 PCG: Yes
Comp.
Het.
R355fsX69 122 11
p. D291G[67, 68] Homo - - 0.00 ± 0.00 41.12 ± 18.19 0 42 PCG: Yes
p. G329S[69] 0.00 ± 0.00 0.00 ± 0.00 PCG: Yes
Comp.
Het.
p.T325SfsX104 0 0
p. R368H[2, 42, 52,
57, 61, 68, 70],[43,
71],[5, 6, 48, 72]
Homo 0.00 ± 0.00 21.29 ± 2.40 0 22 PCG: Yes;
Hetero M292K * in POAG 50 61 POAG: Yes for
Comp. Het;
Comp.
Het.
Comp.
Het.
1546dup10 frameshift
in JOAG
90for
M292K;
0 for
dup/fs
11 for
M292K;
11 for
dup/fs
JOAG: Likely if
accompanied
byMYOC
(Continued)
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Table 1. (Continued)
MutationStudied
[ref.]1
Disease (Genotype
reported)2
2nd mutation
reported (if any)3
Enzyme Activity for mutant
allele studied(% WT)4
Inferred Enzyme
Activity for
Reported Genotype
(% WT)5
Genotype to
Phenotype
correlation
(Yes/No)6
PCG POAG JOAG Retinol Steroid Retinol Steroid
p. E387K[8, 58, 63,
73–77],[14]
Homo - 0.00 ± 0.00 0.00 ± 0.00 0 0 PCG: Yes.
Inconclusive for
Comp Het with
P437L(Biochem
assay not done);
8182delG,268delSNF,
P437L in PCG
JOAG:
Inconclusive
(Biochem assay
not done for
G232R)
Comp.
Het.
Comp.
Het.
G232R in JOAG 0for del 0 for del
p.R444Q[69, 76,
78, 79]
Homo - - 274.15 ± 5.80 25.71± 2.65 274 26 PCG: Yes
Comp.
Het.
3964delC 137 13
p. R469W[44, 68,
80, 81]
Homo - - 124.20 ±25.30 5.79 ± 1.04 124 6 PCG:Yes
p. S28W[15] - - 0.00 ± 0.00 600.41 ± 28.58 POAG:.Yes
Hetero 50 350
p. Y81N[42],[15],
[14],[43]
G61E* 0.00 ± 0.00 10.41 ± 5,50 PCG: No;
Hetero Hetero Hetero 50 55 POAG: Yes;
Comp.
Het.
0 5 JOAG: Yes if
accompanied by
MYOC mutation.
p. Q144H[15] - - 82.67 ± 6.36 14.99 ± 2.08 POAG: Yes
Hetero 91 57
p. Q144R[82],[51] NA - 0.00 ± 0.00 84.80 ± 1.45 0 85 PCG: Predicted
for a
homozygote;
Hetero 50 92 POAG: No
p. M292K[72] - - 181.50 ± 6.84 0.00 ± 0.00 POAG: Yes
Hetero 141 50
Comp.
Het.
R368H* 90 11
p. V409F[15] - - 71.50 ± 12.55 151.49 ± 2.96 POAG:
Inconclusive
Hetero 86 126
p. F445C[82],[51] NA - 226.67 ± 14.53 55.03 ± 1.73 227 55 PCG: Predicted
for a
homozygote;
Hetero 164 78 POAG:
Inconclusive
p. R523T[4] - Homo 210.85 ± 9.93 8.21 ± 7.62 211 8 JOAG: Yes with
potentially
incomplete
penetrance of
PCG.
(Continued)
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For structural studies, 17 out of 23 mutations, located in the resolved regions of the CYP1B1
crystal structure, were taken for NMA and MD analysis [36–39] to evaluate their effects on
CYP1B1 structural flexibility. Emphasis was given on the B-C and F-G block regions, as prior
studies reflected their crucial roles in regulating structural dynamics and ligand tunnels of cyto-
chrome P450 family members [21, 40, 41].
Functional analysis of CYP1B1 mutants
The majority of CYP1B1 mutants show reduced estradiol metabolizing activity. The
enzymatic activities of wild type (WT) and mutant clones were measured to explore whether
the mutant CYP1B1 proteins lack 17β-estradiol metabolizing activity, as described previously
[18]. Three out of six mutants reported only in POAG (Q144H, M292K, R523T) (Fig 1A)
Table 1. (Continued)
MutationStudied
[ref.]1
Disease (Genotype
reported)2
2nd mutation
reported (if any)3
Enzyme Activity for mutant
allele studied(% WT)4
Inferred Enzyme
Activity for
Reported Genotype
(% WT)5
Genotype to
Phenotype
correlation
(Yes/No)6
PCG POAG JOAG Retinol Steroid Retinol Steroid
p. D530G[4] - - 0.00 ± 0.00 88.19 ± 2.60 POAG: No
Hetero 50 94
1, Column 1: Numbers in square brackets represent references to the publications reporting the cited study.
2, Column 2: Abbreviations: NA, not available (mutation reported without genotype); Homo, homozygote; Hetero, heterozygote; Comp Het, Compound
heterozygote. Top, middle and bottom rows represent homozygous, heterozygous and compound heterozygous genotypes, respectively.
3, Column 3: Asterisks indicate that the biochemical assay results for those mutations are available (Please see S3 Table).
4, Column 4: Enzyme activities are shown as percent of the value obtained for the wild type allele ± SEM.
5, Column 5: Enzyme activities for the reported genotypes have been inferred based on an in vitro assay. Top, middle and bottom cells within column 5 in
each row provide the inferred enzyme activities for homozygous, heterozygous and compound heterozygous genotypes, respectively. For homozyotes,
the activity for the reported mutation (1st column) was considered. For heterozygotes, along with the activity of the reported mutation (1st column), the
activity due to the 2nd allele (wildtype) was taken as 100% for calculation. For Compound Heterozygotes, the activity due to the 2ndmutation (if available)
was used for calculation. For deletion/frame shift mutations the enzyme activity has been inferred to be null and the available assay results for the
2ndmutations (marked by asterisk) are given in S3 Table.
6, Column 6: Genotype to phenotype correlation is furnished for only reported genotypes except in two cases (Q144R and F445C) where the published
report for PCG described a single mutation without the accompanying genotype. The basis for Genotype to Phenotype (G2P) correlation is furnished
below:
For PCG:CYP1B1 mediated PCG occurs in an autosomal recessive mode of inheritance.
Hence genotype to phenotype correlation has been proposed based on a biochemical assay done on retinol metabolism by CYP1B1 variant proteins.
Both very low and a large excess of retinoic acid levels interfere with the developmental process. G2P correlation has been proposed based on the
inferred enzyme activity for the reported genotypes only, based on our in vitro assay results for both mutations (in case of a homozygote or compound
heterozygote). If our assay result was not available for the second mutation, an inference has been drawn for the deletion mutation as null activity, but no
correlation was attempted for the missense mutation.
For POAG: POAG is a complex disease, which is mostly caused by the interplay of multiple genes and the environment.
The role of CYP1B1 in the case of POAG has been examined based on the report that a low activity of CYP1B1 would help accumulate intracellular
estradiol, resulting in the over expression of myocillin, and might lead to adult onset glaucoma. However, while the molecular basis for the pathogenesis of
mutant MYOC is known, the potential for over expression of wild-type MYOC causing glaucoma is not yet shown. On the other hand, a higher level of
activity of estradiol metabolism can lead to ROS generation and apoptosis, which could ultimately also lead to POAG pathogenesis.
For JOAG: JOAG is a complex disease caused by the interplay of multiple genes and the environment, and clustering in families is more common than in
POAG.
No speciﬁc role of CYP1B1 has been described, except that it can cause JOAG by a digenic mode of inheritance along with MYOC mutation. However,
on rare occasions, a homozygous CYP1B1 mutation has been reported in JOAG without any evidence for the molecular basis for causality.
doi:10.1371/journal.pone.0156252.t001
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Fig 1. CYP1B1mutants assessed for 17β estradiol and retinol metabolizing activities. Panel A:Most
CYP1B1mutants have lower 17β-estradiol metabolizing activity compared to the wild type protein.
Forty-six hours post-transfection, the steroid metabolism activity of CYP1B1 was measured using the
CYP450-GLO™ Assay kit. Protein expression of the wild type and mutant CYP1B1 at the time of enzyme
assays was estimated by western blot (S3A Fig). Mutations reported to be associated with the type of
glaucoma have been indicated by colored circles (POAG: red; PCG: blue; and POAG+PCG: green). Panel
B:CYP1B1mutants reported in POAG and PCG cases show differential patterns for retinol
metabolizing activity. To assay retinoic acid metabolism activity, HEK 293T cells were transiently
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showed significantly reduced estradiol metabolizing activity (0 to 14.99%, p<0.005) with
respect to the WT control. The fourth mutant (D530G) also showed reduced enzymatic activity
(88.19%±2.60) but the difference was not statistically significant. Interestingly, remaining two
mutants (S28W and V409F) in this category showed significantly higher enzymatic activity.
S28W showed almost 6-fold (600.41% ± 28.58) and V409F showed 1.5 fold (151.49% ±2.96)
higher enzyme activity in comparison to WT. Also, six out of the nine mutants reported for
both PCG and POAG (P52L, G61E, Y81N, R368H, E387K, and F445C) was observed to have
significantly reduced enzyme activity (0 to 71.09%, p<0.05). Q144R also showed slightly
reduced enzyme activity (84.80±1.45). Remaining two mutants, W57C and E229K had almost
3.4 (337.84 ± 20.38) and 1.7 (167.65 ±34.37) fold higher enzyme activity, respectively, in com-
parison to WT. The mutations reported exclusively in PCG (R117W, R117P, M132R, F261L,
D291G, G329S, R444Q, and R469W) were found to have widely varied enzyme activity in the
range of null to 70.63% ± 2.60 (Fig 1A).
CYP1B1 mutants in general show two discrete patterns for retinol metabolizing activ-
ity. In general, either null or significantly higher retinol metabolizing activities were detected
for mutants compared to the wild type protein. Our experimental results indicate that mutations
that were exclusively reported in PCG patients either completely lacked retinol metabolizing
activity (e.g., R117W, R117P, M132R, D291G, and G329S) or showed significantly higher activ-
ity e.g. F261L (243.15 ± 15.48%), R444Q (274.15 ± 5.80%), and R469W (124.20 ± 25.30%)] (Fig
1B). Variants reported for both PCG and POAG also followed a similar pattern (Fig 1B). On the
other hand, mutants reported solely for POAG patients showed a heterogeneous pattern, i.e. (a)
Null: 2 variants (S28W, D530G), (b)Higher than WT: 2 variants M292K (181.50 ± 6.84%),
R523T (210.85 ± 9.93%)] and (c) Slightly Reduced Activity: 2 variants Q144H (82.67 ± 6.36%),
V409F (71.50 ± 12.55%)] (Fig 1B).
It is worth mentioning here that an optimum level of retinol metabolism is required for nor-
mal eye development. Both an excess and a deficiency of vitamin A (retinol) and related com-
pounds (retinoids) has been found to be associated with teratogenesis and malformation of
organs including the eyes [16, 17, 83].
Correlation of translational turnover rate of CYP1B1 mutants with their enzymatic
activities. It is suggested that the differential enzyme activity of different CYP1B1 mutants
may have correlation with their stabilities after protein expression [42, 84–86]. In this context,
we examined the translational turnover rate of the mutant CYP1B1 proteins after addition of
CHX and the subsequent effect on their biological activity. It was observed that 12 out of 23
variants did not show any deviation in decay over the time-course (0, 4, 8, and 12h) from that
of wild type. Among them, F261L, although showing higher level of expression (124.43%±9.12)
at 12h after the addition of CHX, compared to WT, this difference was not statistically signifi-
cant. The remaining 11 mutants (P52L, W57C, G61E, Y81N, R117P, R117W, D291G, E387K,
transfected with different CYP1B1 variant clones and CYP1B1 expression was allowed for 12h. Next, cells
were transfected with an inducible RARE-responsive firefly luciferase construct mixed with a constitutively
expressing Renilla luciferase construct available in the SA-Bioscience Kit. After another 16h, retinol was
added to each well at 2μM concentration. Six hours post retinol treatment, cells were washed and lysed with
luciferase cell lysis buffer. Firefly (FF) and Renilla Luciferase (RL) luminescence was measured using the
Dual Luciferase kit from Promega. Each assay was performed in technical triplicates and repeated three
times. The FF–RLU value was normalized by dividing with RL–RLU value. Cells expressing wild type and
mutant CYP1B1 proteins convert retinol into RA, which binds the inducible-RARE construct and
luminescence is generated. The enzyme activity of the mutant proteins was expressed as a percentage of the
activity retained as compared to the native (wild type) enzyme. Protein expression of the wild type and mutant
CYP1B1 at the time of enzyme assays was estimated by western blot (S3B Fig) Data represent the
mean ± SEM for a triplicate per group. Data were tested with an unpaired t test. Differences in mean values
were assessed for statistical significance (*, p< 0.01). Experiments were repeated three times.
doi:10.1371/journal.pone.0156252.g001
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R444Q, R523T, D530G) were found to be less stable after the addition of CHX (Fig 2). Three of
these mutants viz. R117P (reported only in PCG), R523T (reported only in POAG) and E387K
(reported both in PCG and POAG) showed little or no expression at 4h after the addition of
CHX. For these mutants we estimated the protein levels at time intervals of a shorter duration
(15min, 30min, 1h, 2h and 3h) after the addition of CHX (S4 Fig). In case of R117P, the trans-
lational arrest started immediately after 30 min of CHX treatment and showed almost no
detectable protein level by 3h. E387K and R523T showed relatively greater stability compared
to R117P. While the expression of E387K began to decline from 1h after CHX addition, R523T
was stable up to 3h (S4 Fig).
Among the 11 mutants with lower stability, it was observed that the instability of seven
(P52L, G61E, Y81N, R117W, D291G, E387K, D530G) could result in a reduction in both the
estradiol- and RA- metabolizing activities (Fig 1A and 1B), i.e. the unstable nature of these
mutant proteins was possibly the cause of their lower enzymatic activities. In contrast, a direct
correlation is lacking for the other 4 mutants (W57C, R117P, R444Q, and R523T). In the case
of R117P, estradiol metabolism was found to be almost similar to WT (Fig 1A), while in
W57C, R444Q and R523T, retinol metabolism was found to be a few folds higher (Fig 1B).
The apparent lack of correlation for these 4 mutants could possibly be due to their different
rates of translational turnover over the course of time when assays were done without addition
of CHX (S5 Fig). Our results revealed that the increase in level of protein expression of these
mutants (W57C, R117P, R444Q, and R523T) was quite low during the initial hours (S5 Fig),
which gradually reached almost comparable levels with WT when enzyme assays were done
(i.e. 36h for retinol, and 46h for estradiol metabolizing assay). At 14h after transfection (i.e.
CHX addition time point), the expression of these mutants was already low, and after inhibit-
ing protein synthesis with CHX the levels decreased further. Thus, if the results for these
mutants are viewed along with other mutants, the low level of signal at early time points may
appear to be due to low stability for these mutants, which is not supported by following the
assay for a longer period without addition of CHX (S5 Fig). Therefore, the lack of correlation
of these four mutants with the phenotype might be the limitation of the in vitro assay, resulting
from slower translation rates of these mutant proteins.
Structural analysis of CYP1B1 mutants
Our functional data indicate that mutations reported in PCG patients either completely lacked
retinol metabolizing activity or showed significantly higher enzyme activity compared to WT.
On the other hand, estradiol metabolism activity was spread over in the range of 36.33% ± 2.09
to 89.53% ± 2.24. First, we were interested in investigating the structural reason behind two dis-
tinct functional results observed in the case of retinol metabolism. NMA analysis of only PCG-
causing mutants showed a similar trend of flexibility in the B-C and F-G block regions (S2C
Fig) with R117P and F261L mutants showing the highest extent of altered flexibilities. We
selected these two mutant proteins for further in-silico structural analysis.
In the case of POAGmutants and POAG+PCG cases (S2C Fig), no specific flexibility pat-
tern was observed. However, Q144R, which is involved in both PCG and POAG pathogenesis,
and showed flexibility similar to that of only PCG causing mutants, and an exclusive POAG-
causing mutation involving the same residue (Q144H) were also selected for further in depth
Molecular Dynamic (MD) based structural analysis. Notably, Q144R caused null retinol
metabolism and almost normal steroid metabolism, whereas Q144H showed slightly reduced
retinol metabolism and significantly reduced steroid metabolism activity.
Lower flexibility in crucial loops and gain of ligand tunnel pathway in F261L might cause
gain of function in retinol metabolism. The PCG causing F261L mutant shows higher retinol
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Fig 2. Protein turnover rate of CYP1B1 constructs. Transfected HEK 293T cells were treated with CHX for
12h to inhibit protein synthesis. Twenty μg cell extracts were probed sequentially, by western blot analysis, with
appropriate antibodies: Myc (to detect recombinant CYP1B1) Cell Signaling Technology, USA] and β-actin (to
serve as a loading control) (Sigma, USA). Immunoblots were scanned, and net pixel intensities of the bands
were measured with Image J software. CYP1B1 values were normalized to β-actin, the mean values were
taken for three separate transfections, and the relative amounts of CYP1B1 were expressed as a percentage of
levels of WT at respective time points. Representative lanes from western blots are furnished on the right side of
the panels. Panel A:Mutations found in only POAG cases; Panel B:Mutations found in both POAG and PCG
cases; Panel C:Mutations found in only PCG cases. Level of WT protein under similar conditions is shown in
panel A. Data represent the mean ± SEM for a triplicate per group. Data were tested by an unpaired t test.
Differences in mean were assessed for statistical significance (p< 0.01). Experiments were repeated three
times.
doi:10.1371/journal.pone.0156252.g002
Molecular Basis of CYP1B1 Induced PCG and POAG
PLOSONE | DOI:10.1371/journal.pone.0156252 May 31, 2016 13 / 30
activity compared to the wild type protein. MD simulations of F261L with retinol showed that
the essential dynamics (ED) (please refer to S1 Method for details about the ED analysis) [36–
39, 87–91] of the mutant is relatively similar to its WT counterpart (Fig 3A and S6 Fig), suggest-
ing unchanged functional motions between the F261L andWT structures. However, root mean
square fluctuation (RMSF) of the C-D, F and G'-H block residues of the F261L protein showed
the most altered flexibility compared to WT (Fig 3B and S7A Fig). Earlier studies [19–21]
showed that these blocks are important for regulating the dynamics of cytochrome P450 family
members and ligand tunnel formation. A mutation within these blocks may influence the struc-
tural flexibility as well as ligand tunnel properties. To understand the effect of the mutation on
tunnels, we carried out tunnel analysis using the CAVER 3.0 [35] program. Results showed a
retinol-specific tunnel in F261L near the F/G region with a shorter length and broader radius
(top view of Fig 3C and upper panel of Tunnel properties), while the bottom view tunnels pos-
sess similar tunnel properties as that of theWT protein (Fig 3C, lower panel of Tunnel proper-
ties). Altered flexibility was also observed to influence the residues surrounding the tunnel
( 5Å radius) (S7B Fig). MD simulations showed a lower retinol binding energy profile in the
mutant (a 4.2% increase in overall retinol binding energy is observed as compared toWT) (Fig
3D and S7C Fig) and an altered distribution of the Asp, Ile and Leu residues surrounding
( 5.0Å) the retinol substrate bound to F261L (S7D Fig) when compared to theWT.
Altered structural flexibility in the R117P mutant probably leads to heme instability,
causing loss of retinol metabolism activity. A sequence and structural analysis of cyto-
chrome P450 proteins showed that R117 of CYP1B1 is absolutely conserved among its family
members (Fig 4A, upper panel) and forms a hydrogen bond with the O1A/O2A atom of the
heme ligand (Fig 4A, lower panel). Thus in the R117P mutation, the loss of this crucial hydro-
gen bond interaction with the O1A/O2A atom might cause reduced heme binding stability.
The ED distribution (please refer to S1 Method for details) (Fig 4B and S6 Fig) between WT
and R117P protein indicates the existence of relatively distant functional motions between the
two proteins. However, the RMSF analysis of R117P showed a significant altered fluctuation
within the B-C, G-H and J-K regions (Fig 4C and S8A Fig). Contact analysis of heme O1A/
O2A atom within 3.5Å of radius (S8B Fig) showed altered interacting residues with the O1A/
O2A atoms, probably arising from the change in the mutant protein flexibility. The probable
loss of the heme interactions is also visible from the differences in root mean square deviation
(RMSD) (Fig 4D) and average bond angle deviation (Fig 4E) matrices of heme, where fluctua-
tions and bond angle deviations in the initial stages of MD simulation indicate a potentially
higher instability in the heme of the mutant protein.
Altered structural flexibility and ligand tunnel properties in Q144R mutant might cause
the loss of retinol metabolism activity. Q144R CYP1B1 showed a null retinol and almost
similar 17β-estradiol activity to WT. It is reported for both PCG and POAG pathogenesis. The
difference in ED distribution (please refer to S1 Method for details) observed fromMD simula-
tions of WT and Q114R mutant in the presence of retinol can be related to the null activity of
Q114R in retinol metabolism (Fig 5A). Comparison of the Q144R RMSF with that of WT (Fig
5B and S9A Fig) showed a decrease in B-C loop, G helix flexibility and an increase in C and D
helix flexibility. Significantly altered regions are shown separately in the right hand side of the
panel in Fig 5B. Similarly, a comparative tunnel analysis of both the WT and mutant structures
showed the presence of an altered retinol-specific tunnel in Q144R (Top view, Fig 5C). The
tunnel properties of Q144R showed that the top view tunnels have a similar tunnel radius and
a longer length (Fig 5C, upper panel of "Tunnel properties") compared to that of the WT. In
bottom view tunnels, a moderate increase in tunnel radius and length (Fig 5C, lower panel of
"Tunnel properties) was observed as compared to the WT protein. Tunnel lining residues
( 5.0Å) were also found to be different in Q144R as compared to the WT tunnels (S9B Fig).
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Retinol binding in Q144R showed a slightly higher retinol binding energy compared to the WT
structure, especially around 80–100 ns (a 0.13% decrease in overall retinol binding energy is
observed in mutant as compared to WT) (Fig 5D and S9C Fig). A contact residue analysis
( 5.0Å) of retinol (S9D Fig) showed that the type of residues surrounding the bound retinol is
Fig 3. MD simulation analysis of the F261L and wild type CYP1B1 structures. Panel A shows a similar distribution of the first three major principal
components of F261L and wild type (WT) CYP1B1 structures, suggesting relatively unchanged functional motions in the F261L mutant as compared to
theWT structure. Panel B shows the altered flexibility pattern of the F261L mutant as compared to wild type. The log2ratio is calculated as
log2
RMSF value of ith residue in F261L=RMSF value of ith residue in WT
 
. Therefore a positive value indicates an increase in ﬂexibility in the F261L mutant and a negative value
indicates a decrease in ﬂexibility as compared to WT CYP1B1. F261L mutant has a signiﬁcantly altered ﬂexibility pattern within the C-D, F and G'-H block
regions, shown separately in the right hand side of the panel. Panel C shows the altered tunnels in two different orientations (top and bottom view) of the
F261L andWT CYP1B1 structures. The upper panel of "Tunnel properties" shows the radius (in bar plot) and length (in black line) of the tunnels (Top
view orientation) in the mutant (orange) andWT (green) structures while the lower panel shows the similar properties of tunnels observed in the bottom
view orientation. Panel D shows docked retinol in the WT and F261L mutant CYP1B1 structures. The panel also shows an overall increase in binding
energy in F261L mutant retinol binding observed through MD simulation.
doi:10.1371/journal.pone.0156252.g003
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Fig 4. MD simulation analysis of the R117P and wild type CYP1B1 structures. Panel A shows a multiple sequence alignment of CYP1B1 homologs.
The red color indicates the conserved Arginine 117 position in other homologs. Thelower panel shows the structural importance of Arginine 117in their
interaction with the O1A/O2A atom of the heme ligand. Panel B shows a similar distribution of first three major principal components of R117P and wild
type (WT) CYP1B1 structures. Panel B shows that the R117Pmutant possesses a significantly altered flexibility pattern within the B-C, G-H, and J-K
block regions. Panel C shows the altered flexibility pattern in the R117Pmutant as compared to WT. The log2 ratio is calculated as
log2
RMSF value of ith residue in R117P=RMSF value of ith residue in WT
 
. Therefore, a positive value indicates an increase in ﬂexibility in the R117Pmutant and a negative
value indicates a decrease in ﬂexibility as compared to WT CYP1B1. The R117Pmutant has a signiﬁcantly altered ﬂexibility pattern within the B-C, G-H
and J-K block regions, shown separately in the right hand side of the panel. Panels D and E illustrate RMSD deviation and average bond angle deviation
of the heme ligand in ΔRMSD and Δdegrees matrices, respectively. The difference matrices were calculated by subtracting RMSD and average bond
angle values of mutant CYP1B1 from that of WT CYP1B1. The ﬂuctuations and bond angle deviations in the initial stages of the MD simulation indicate a
potential instability in the heme ligand binding afﬁnity within the mutant protein.
doi:10.1371/journal.pone.0156252.g004
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similar in Q144R apart from the presence of a high frequency of Phe and a low frequency of
Leu residues as compared to the WT.
Lower flexibility in crucial loops and the loss of a ligand tunnel pathway in Q144H prob-
ably caused the significantly reduced estradiol metabolism. Q144H CYP1B1 shows a
Fig 5. MD simulation analysis of the Q144R and wild type CYP1B1 structure. Panel A shows the distribution of the first three major principal
components of the Q144R and wild type (WT) structures. The distributions are observed to be different, suggesting an altered functional motion in the
Q144Rmutant. Panel B shows the altered flexibility pattern of the Q144Rmutant as compared to WT. The log2 ratio is calculated as
log2
RMSF value of ith residue in Q144R=RMSF value of ith residue in WT
 
. Therefore a positive value indicates an increase in ﬂexibility in the Q144Rmutant and a negative
value indicates a decrease in ﬂexibility as compared to WT CYP1B1. The Q144Rmutant has a signiﬁcantly altered ﬂexibility pattern within the C-D, F and
G'-H block region, shown separately in the right hand side of the panel. Panel C shows the altered tunnels in two different orientations (top and bottom
view) of the Q144R andWT CYP1B1 structures. The upper panel of "Tunnel properties" shows the radius (in bar plot) and length (in black line) of the
tunnels (top view orientation) in the mutant (blue) andWT (green) structures. The lower panel shows the similar properties of the tunnels observed in the
bottom view orientation. Panel D shows docked retinol in the WT and mutant CYP1B1 structures. The panel also shows an overall decrease in binding
energy in retinol binding for the mutant protein, observed through MD simulation.
doi:10.1371/journal.pone.0156252.g005
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reduced estradiol activity and is associated with POAG. In this case, MD simulation of 17β-
estradiol docked Q144H andWT CYP1B1 structures were performed and subsequent ED anal-
ysis (please refer to S1 Method for details) showed a similar distribution of the first three prin-
cipal components between the Q144H andWT structures (Fig 6A). The B-C and F-G block
Fig 6. MD simulation analysis of the Q144H andWT CYP1B1 structures. Panel A shows marginally similar distributions of the first three major
principal components of the Q144H and wild type (WT) CYP1B1 structures. Panel B shows that the Q144Hmutant possesses a significantly altered
flexibility pattern within the B-C, F-G and H block regions. The log2 ratio is calculated as log2
RMSF value of ith residue in Q144H=RMSF value of ith residue in WT
 
. Therefore, a
positive value indicates an increase in ﬂexibility in the Q144Hmutant and a negative value indicates a decrease in ﬂexibility as compared to WT CYP1B1.
The signiﬁcantly altered ﬂexible regions are shown separately in the right hand side of the panel. Panel C shows the altered tunnels in two different
orientations (top and bottom view) of the Q144H andWT CYP1B1 structures. Interestingly no tunnel was observed in the top orientation of the Q144H
structure. The upper panel of "Tunnel properties" shows the radius (in bar plot) and length (in black line) of the tunnels (Top view orientation) in the
mutant (pink) andWT (green) structures. The lower panel shows similar properties of tunnels observed in the bottom view orientation. Panel D shows
docked retinol in theWT and mutant CYP1B1 structures. The panel also shows an overall decrease in binding energy in retinol binding for the mutant
protein, observed through MD simulation.
doi:10.1371/journal.pone.0156252.g006
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residues of Q144H showed reduced flexibilities while an increase is observed in H-helix flexi-
bility (Fig 6B and S10A Fig). The tunnel analysis showed the loss of a tunnel in Q144H as com-
pared to the wild type structure (Fig 6C, top view panel) but the bottom view panel (Fig 6C)
showed the presence of 17β-estradiol-specific tunnels in both the Q144H and WT structures.
However, the tunnels of Q144H in the bottom view region showed better tunnel properties
compared to the WT protein (Fig 6D, lower panel of “Tunnel properties”). The overall binding
energy of 17β-estradiol in Q144H obtained fromMD simulation was slightly decreased as com-
pared to its WT form (a 0.35% decrease in overall retinol binding energy is observed as com-
pared to WT) (Fig 6D and S10B Fig) and the number of hydrogen bonds formed by 17β-
estradiol was much lower in Q144H compared to WT (S10C Fig).
Genotype to phenotype analysis for CYP1B1 variants implicated in
POAG and PCG
We hypothesize that the genotype of CYP1B1 in an individual, activity of the expressed gene
product towards its substrate (retinol and estradiol), along with other, yet undescribed, factors
finally determine the manifestation of the glaucoma phenotype. Thus, a CYP1B1 variant for
which the retinol metabolic activity is critically low, if present as homozygous or compound
heterozygous state with a similar metabolic fate, would result in a PCG phenotype. However, a
carrier of a single allele of such a functionally deficient variant will not have the disease—as
typically expected for an autosomal recessive mode of transmission. Similarly, an individual
carrying a CYP1B1 variant that has no effect on retinol activity, but is deficient in metabolizing
estradiol, would not have PCG phenotype even with a homozygous genotype, but would be
likely to have POAG as an adult.
It is also worthwhile to mention here, as previously described, that a complete lack of and an
excess of retinol and retinoids are both associated with the malformation of organs, including
the eyes [16, 17, 83]. Hence, a CYP1B1 variant that results in a few fold higher activities relative
to normal might also cause PCG depending on its level of expression during development.
Table 1 summarizes the genotypes in PCG and POAG patients, enzymatic activities,
inferred CYP1B1 activities, and the possible explanations for disease pathogenesis for each
mutation. It was observed that all of the mutants that are reported to be in homozygous or
compound heterozygous condition in patients show either very high or null retinol metabolism
in the vitro assay (Table 1, Fig 1B). We propose that this distinct alteration in retinol metabo-
lism in individuals bearing these mutants resulted in PCG. On the other hand, mutants appear-
ing in heterozygous condition with low or much higher estradiol metabolism activity mostly
leads to the development of POAG.
In such cases, where a single heterozygous mutation in CYP1B1 has been reported in a PCG
patient, it is likely that either CYP1B1 is not the underlying causative gene in the patient or the
second mutation in the gene is present but not identified. On the other hand, in the case of
POAG patients, where the reported CYP1B1 mutations are present in heterozygous condition,
a single dose of the WT allele produces necessary threshold amount of RA for normal eye
development. If a single defective allele, acquires very high retinol metabolism activity (enough
to produce a teratogenic effect) in any patient, it could lead to the precipitation of PCG.
A comprehensive understanding of our hypothesis is depicted in the proposed model of dis-
ease occurrence (Fig 7).
Discussion
CYP1B1 is a multifunctional enzyme with diverse substrate specificity, known to be involved
in the onset of PCG and POAG. However, the functional role of mutated forms of this enzyme
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in the different forms of glaucoma is not well understood. In the current study, we attempted
to correlate retinol metabolism with glaucoma pathogenesis, especially with PCG, in a cell cul-
ture system through an extensive study with 23 CYP1B1 mutations. Notably, it was evident
from our genotype to phenotype correlation analysis that dysfunction in one CYP1B1 allele is
sufficient to cause disorders like POAG, as CYP1B1mutations occur mostly in heterozygous
condition in these diseases, but not in PCG where defects of both the alleles are required for
precipitation of the disease phenotype.
Both mouse and human CYP1B1 orthologs can metabolize retinol and retinal to RA. RA is
the ligand for nuclear retinoic acid receptors (RAR) and retinoate X-receptors (RXR). The
binding of RA to these receptors results in transcriptional activation of various other genes
involved in normal developmental processes. In the present study, we found that CYP1B1
mutations that are reported only in PCG or both PCG and POAG patients showed either null
or over-production of RA. A previous study reporting four mutations in PCG patients (Y81N,
E229K, A330F, R368H) showed that retinoid metabolism was severely impaired in the Y81N
and R368H mutants, moderately in A330F, and slightly in E229K [84]. Our results with the
Y81N and, R368H mutants in the HEK cell line are similar to the previous report, but E229K
shows slightly higher activity with respect to WT. The assays done in the previous study is dif-
ferent from ours: The mutant proteins were expressed in bacteria, isolated, and then assayed.
In contrast, we have done the experiment in a cell-based system, transfected HEK cells with
mutation-specific clones and then estimated the activity in the cell extract. Thus, some differ-
ences between the results of the two studies would not be entirely unexpected. Moreover, this
result is consistent with the evolutionary conservation of positions Y81 and R368, but not
of E229 throughout orthologs and paralogs in different mammalian species, as previously
reported [15]. Similarly, it has been reported in an animal study that an optimum retinol
metabolism is necessary for normal eye development; deprivation or excess feeding with
Fig 7. Genotype to phenotype correlation for the role ofCYP1B1 in glaucoma pathogenesis (PCG vs
POAG). The flowchart shows the potential activity of CYP1B1 variants for two different substrates (estradiol and
retinol), as estimated by an in vitro cell based assay in HEK293T cells and attempted correlation of the biochemical
activities (based on genotype) with potential glaucoma pathogenesis. Ref.(1)[18]; Ref.(2,3)[92, 93]; Ref.(4)[17];
Ref.(5,6)[17, 83].
doi:10.1371/journal.pone.0156252.g007
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vitamin A metabolites (RA in particular) to pregnant mammals has been found to be associated
with malformation of the eyes [94].
Further, our results showed that most of the POAGmutations caused reduction in CYP1B1
steroid metabolizing activity, providing further credence to the preliminary observation made
previously from a much smaller sample size [18]. It is believed that in the case of steroid induced
glaucoma, over-expression of myocilin is one of the triggering factors for glaucoma causation;
however, the notion is still controversial.
Four mutants, S28W, W57C, E229K and V409F showed higher enzymatic activities relative
to the WT control, respectively. A previous report showed that a higher enzymatic activity of
CYP1B1 caused accumulation of excess 4-OH-estradiol, leading to formation of quinones.
Quinones can create oxidative stress and induce ROS generation, which may cause cell death
in TM and retinal ganglion cell and thus could be involved in POAG pathogenesis [92, 93, 95].
Our results for assay for selected mutants are overall similar to the previously reported data
with larger variation in a few cases (e.g. P52L, R117W, and E229K). Notably, in three different
previous studies [18, 42, 84] E229K showed variable enzyme activity, as also in our present
study. This might result from use of different expression vectors, different cell lines, substrate
analogues and the method used for assay.
The underlying reasons for the differential activity of the variant CYP1B1 proteins could be
different. It was interesting to note that 11 out of 23 mutants had lower stability relative to WT
CYP1B1. This observation is not surprising since all 11 variants produced nonconservative
missense mutations with side chains greatly dissimilar fromWT. While the unstable nature of
the seven mutant proteins was possibly the cause of their lower enzymatic activity, this obser-
vation did not appear to hold for the remaining four mutants. In the case of these four mutants,
the rate of translation increased slowly and steadily up to the maximum period of tracking
(46h), but appeared to be less stable when the translation was arrested at an early time point
with CHX due to a lower accumulation of protein. This observation was consistent with the
expression levels of these four mutants as measured from the lysates of cells untreated with
CHX (S5 Fig).
We performed extensive NMA, MD simulations and structural analyses to understand the
probable structural alterations in the mutants of the CYP1B1 protein that led to widely varied
functional results. We observed significant variation in the fluctuation of certain segmental
parts of the mutant proteins with respect to their WT counterpart through NMA studies. The
change in fluctuation within and surrounding the B-C and F-G loop region was previously
known to affect the dynamic behavior and ligand entry/exit properties of the CYP1B1 family of
proteins [36–39]. Our computational analyses showed that the relatively higher retinol metab-
olism activity of the F261L mutant could be a result of additional retinol-specific tunnels with
lower path length and higher diameter, leading to improved retinol binding in F261L com-
pared to the WT CYP1B1. Further, our structural analyses suggested that altered essential
motions and fluctuations as a reflection of the R117P mutation might lead to compromised
heme binding stability. Similarly, the null retinol biochemical activity of the Q144R mutation
can also be attributed to the significantly changed motions of the crucial B-B’, C-D loop
regions. Our study also indicated that the Q144R mutation might generate altered retinol-spe-
cific ligand tunnels, leading to compromised retinol entry/exit to the active site. On the other
hand, the Q144H mutant shows lower 17β-estradiol metabolism activity and MD simulation
analysis revealed that essential motions and fluctuation of the B-C, F-G and H block regions
were significantly changed. The binding energy and hydrogen bonding profile (S9B Fig) of the
Q144H mutant model suggested slightly decreased binding capability to 17β-estradiol. All of
the results and possible effects of the tested mutations on the CYP1B1 structure are summa-
rized in Fig 8.
Molecular Basis of CYP1B1 Induced PCG and POAG
PLOSONE | DOI:10.1371/journal.pone.0156252 May 31, 2016 21 / 30
It was observed that most of the PCG causing mutations in CYP1B1 are present as homozy-
gous or compound heterozygous genotype whereas POAG causing mutations were heterozy-
gous with very few exceptions. Thus, in most of the cases of PCG, we were able to relate the
reported genotype with observed disease phenotype (Table 1). Additionally we could identify
the cases where the genotype data are not consistent with our hypothesis based on the esti-
mated RA metabolizing activity and speculate the reason.
Fig 8. Summary of possible effects of mutations on CYP1B1 structure observed through MD simulation.
doi:10.1371/journal.pone.0156252.g008
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Our results are also consistent with the observation that a mutation in a single allele of
CYP1B1 induces late onset glaucoma (i.e. POAG) due to the lower steroid metabolism of the
mutant allele, as explained earlier. However, there are reports of a few exceptional cases where
this genotype to phenotype correlation did not follow. For example the P52L, Y81N and
E229K mutations were found in PCG patients in heterozygous conditions. It is interesting to
note that close relatives of the PCG patients carrying the P52L and Y81N mutations with the
same genotype were found to be unaffected [42, 58]. We predict that some unidentified genetic
factors other than a mutation in CYP1B1might have role in PCG causation in these patients.
Multiple reports of heterozygous E229K mutations in PCG cases suggest the involvement of an
unidentified mutation in the other allele [5]. It is noteworthy that, the identical twin brother of
a JOAG patient carrying a G61E [50] mutation had PCG. We assume that there might be other
epigenetic and environmental factors that are responsible for controlling PCG onset in these
cases provided there was no genotyping error.
Finally, our observations reveal that the mutations, that caused severe alteration in RA-metab-
olism without any comprehensive alteration in estradiol metabolism activity, were responsible
solely for PCG pathogenesis (R117P and Q144R), whereas, the mutations that caused steroid
metabolism dysfunction without any significant alteration in retinol metabolism were responsi-
ble for POAG (Q144H, V409F). However, Q144R has also been reported in the case of a single
POAG patient [51]. We argue that this variant may not be associated with suspected POAG
pathogenesis; the variant was found to have 17β-estradiol metabolism activity similar to theWT
allele. Thus, this case further lends support to the argument that the association of a genomic var-
iant with a phenotype should be examined by alternation of relevant biological function of the
mutant molecule. The cases of mutations reported for both PCG and POAG also showed dys-
function in both the enzymatic activities. This may imply that if these mutations are present in
heterozygous condition, the carrier of the mutation is able to acquire the threshold level of RA
and escapes PCG but the onset of POAG takes place due to a reduction of steroid metabolism at
a later age. Our hypothesis is supported by the reported occurrence of two glaucoma patients in a
family: (i) a PCG patient carrying F261L and R355fsX69 in CYP1B1, and (ii) an ocular hyperten-
sic patient carrying a single mutation (F261L) in CYP1B1 [42]. A more recent study by Lopez
Garido et al [96] showed the coexistence of POAG and PCG phenotypes in the same family. The
grandmother of the proband, heterozygous for a CYP1B1 mutation was detected with POAG at
the age of 70, where as the proband with the same mutation in compound heterozygous condi-
tion along with a frame-shift mutation manifested PCG, strongly supporting our hypothesis.
Our study is highly suggestive of dual effect of CYP1B1 in the families harboring mutation
in the gene. We propose that the heterozygous parents of a PCG-affected child due presence of
two defective alleles of CYP1B1 are prone to late onset glaucoma due to altered metabolizing
activity of 17β-estradiol relative to the normal levels. This hypothesis could directly be tested in
the CYP1B1mediated PCG family by a study design that include long term follow up of the
members of the families harboring the mutant CYP1B1 allele in heterozygous condition. In the
current study, we investigate the effect of several disease causing mutations in CYP1B1 on the
biological activity of the protein. In many cases we were able to relate the measured enzymatic
activities of the CYP1B1 mutants with disease pathogenesis, suggesting that functional analysis
of any suspect variants in CYP1B1 could be predictive of disease pathogenesis, depending on
the specific genotype at the given locus.
Supporting Information
S1 Fig. Endogenous expression of CYP1B1 in Trabecular Meshwork (TM) and HEK293T
cell line. Each lane contains cell lysate corresponding to 20μg of total protein. CYP1B1 were
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detected by immunoblot using a monoclonal anti-CYP1B1-antibody (Santa Cruz Inc, USA). β-
actin was detected using an anti-β-actin-antibody (Sigma, USA).
(TIF)
S2 Fig. CYP1B1 gene showing its different domain with naturally occurring missense
mutations on it. Panel A illustrates mutations distributed on CYP1B1 gene showing lack of
any disease specific clustering of mutations. Panel B shows mutations selected for this study
and the associated disease phenotypes are indicated by color code mentioned in the figure.
Panel C shows the log transformed fluctuation ratio of the CYP1B1 mutants to CYP1B1Wild
Type structure. The fluctuations were obtained through normal mode analysis method. Panel i
(left upper two panels) shows the fluctuation ratio of only PCG causing CYP1B1 mutants.
F261L and R117P showed the highest extent of altered flexibility within the same B-C and F-G
block region. Panel ii (lower left panel) shows the fluctuation ratio of only POAG causing
CYP1B1 mutants but no specific altered flexibility is observed within the structure. Panel iii
(right panels) displays both PCG and POAG causing CYP1B1 mutants. Q144R shows the high-
est extent of altered flexibility as compared to other known PCG and POAG causing mutants.
(TIF)
S3 Fig. The protein levels of different CYP1B1 mutants present in transiently transfected
HEK293T cells are shown at the time of estradiol metabolism (46h) assay in Panel A and at
the time of retinol metabolism assay (36h) in Panel B. Each lane contains cell lysate corre-
sponding to 20μg of total protein. CYP1B1 polypeptides tagged with myc-epitope at their C-
terminal end were detected by immunoblot using a monoclonal anti-myc-antibody. β-actin
was detected using an anti-β-actin-antibody.
(TIF)
S4 Fig. Representative graph & western blots showing stability of three CYP1B1 variants at
0 min, 15 min, 30 min, 1h, 2h, 3h and 4h after inhibition of translation by CHX treatment.
These mutants showed very little or no expression at 4 hours of treatment.
(TIF)
S5 Fig. Percent expression of mutants (with respect to WT) at 14h, 18h, 22h and 26h with-
out addition of CHX.
(TIF)
S6 Fig. Euclidean distance of the Principal Components shows the relative similarity of
each mutant with respect to the wild type CYP1B1 structure. The Euclidean distance among
the three principal components (PC) can be calculated as follows:
Euclidean distance
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðPC1Wild type  PC1MutantÞ2 þ ðPC2Wild type  PC2MutantÞ2 þ ðPC3Wild type  PC3MuatntÞ2
q
(TIF)
S7 Fig. Panel A shows that F261L mutant has a significantly altered flexibility pattern within
the C-D, F and G’-H block region. Panel B shows the tunnel surrounding residues (5Å
radius) in both the mutant and wild type structures. Panels C and D describe the binding
energy profile and the surrounding residues of retinol within the F261L and wild type struc-
tures.
(TIF)
Molecular Basis of CYP1B1 Induced PCG and POAG
PLOSONE | DOI:10.1371/journal.pone.0156252 May 31, 2016 24 / 30
S8 Fig. Panel A shows that R117P mutant possesses a significant altered flexibility pattern
within the B-C, G-H, and J-K block regions. Panel B shows the contact analysis of heme O1A/
O2A atoms within its surrounding3.5Å radius.
(TIF)
S9 Fig. Panel A shows that Q144R mutant has a significantly altered flexibility pattern within
the B-B’, C-D, and G block region. Panel B shows the tunnel surrounding residues ( 5Å
radius) in both the mutant and wild type structures. Panels C and D describe the binding
energy profile and the surrounding residues of retinol within the Q144R and wild type struc-
ture.
(TIF)
S10 Fig. Panel A shows that Q144H mutant possesses a significant altered flexibility pattern
within the B-C, F-G and H block regions. Panels C and D describe the binding energy profile
and the number of hydrogen bonds between estradiol and surrounding residues within the
Q144H and wild type structure.
(TIF)
S1 Method. Detailed Methodology of Molecular modelling and Docking analysis and
Essential dynamics and Principal Component analysis have been provided with relevant
references.
(DOCX)
S1 Table. List of subclones with their association with different diseases & primer
sequences for site directed mutagenesis.
(DOCX)
S2 Table. Optimization of concentration of CHX onWT at different time points.
(DOCX)
S3 Table. The available assay results for the second mutations of compound heterozygous
genotypes related to Table 1.
(DOCX)
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